TY  - JOUR
AU  - Ehninger, Dan
AU  - Neff, Frauke
AU  - Xie, Kan
TI  - Longevity, aging and rapamycin.
JO  - Cellular and molecular life sciences
VL  - 71
IS  - 22
SN  - 1420-682X
CY  - Cham (ZG)
PB  - Springer International Publishing AG
M1  - DZNE-2020-03951
SP  - 4325-4346
PY  - 2014
AB  - The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
KW  - Aging
KW  - Animals
KW  - Antibiotics, Antineoplastic: pharmacology
KW  - Gene Expression Regulation: drug effects
KW  - Humans
KW  - Longevity: drug effects
KW  - Neurons: drug effects
KW  - Neurons: metabolism
KW  - Signal Transduction: drug effects
KW  - Sirolimus: pharmacology
KW  - TOR Serine-Threonine Kinases: metabolism
KW  - Antibiotics, Antineoplastic (NLM Chemicals)
KW  - TOR Serine-Threonine Kinases (NLM Chemicals)
KW  - Sirolimus (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25015322
C2  - pmc:PMC4207939
DO  - DOI:10.1007/s00018-014-1677-1
UR  - https://pub.dzne.de/record/137629
ER  -